Dr. Christian Kilger

  • Dipl. Biol. Univ., Ludwig-Maximilians Universität München
  • Dr. rer. nat., Ludwig-Maximilians Universität München
  • Patentanwalt
  • European Patent and Trademark Attorney

Dr. Christian Kilger was born in the United States and grew up in both Germany and the U.S. After studying genetics and biochemistry at the Ludwig-Maximilian’s University of Munich he completed his Dr. rer. nat. in Molecular Biology investigating new nucleic acid sequencing technologies in the laboratory of Prof. Svante Pääbo. As a Postdoc at the Max-Planck-Institute for Evolutionary Genetics, Dr. Kilger was a frequent lecturer, also at the European Molecular Biological Laboratory.

In 1997 Dr. Kilger joined LION bioscience AG a NASDAQ traded biotech company, where he was responsible for all global IP matters during its initial public offering on the German Stock exchange and the NASDAQ in the USA.

In 2005 Dr. Kilger joined the IP law firm Boehmert & Boehmert. Dr. Kilger then headed the Berlin office of Vossius & Partner. In 2012 Dr. Kilger founded CH KILGER Anwaltspartnerschaft mbB with its main office in Berlin and offices in Munich and Buenos Aires, Argentina.

Dr. Kilger has represented numerous Biotech, Pharmaceutical, Diagnostic, Food/Beverage clients in complex opposition and patent infringement proceedings. Dr. Kilger is the author of numerous articles relating to the patenting of biotechnological inventions and frequently lectures in this field. He has served as an advisor to the State of Berlin, the World Intellectual Property Organization, the European Patent Office and the German Federal Ministry of Research on various IP issues. Dr. Kilger has repeatedly been mentioned in the Legal 500 and in JUvE.

In 2013 Dr. Kilger received the International Client Choice Award in Intellectual Property Healthcare & Life Sciences.

Exemplary opposition, FTO, prosecution and patent infringement proceedings:

  • EP-B1 1 530 578 QIAGEN GmbH ./. ILLUMINA (USA), opposition and patent infringement suit;
  • EP-B1 1 638 704 Big Bell Solar ./. ECOTEC GmbH and ECONX (NL), representing alleged infringer in patent infringement suit and nullity action;
  • DE 196 55 282 represented alleged infringer in patent infringement suit and nullity action to the Germen Federal Supreme Court;
  • EP-B1 0 711 179 IMCORE ./. ACUSPHERE represented IMCORE in opposition;
  • EP-B1 0 810 030 QIAGEN GmbH ./. APPLERA Corp. USA, opposition and patent infringement suit;
  • Acquisition of DIAGENE by QIAGEN (HPv testing) for close to a billion USD; Due Diligence on behalf of QIAGEN;
  • STAT-Dx (multiplex PCR diagnostics) patent counsel until acquired for about 200 Mio USD;
  • EngMAB (anti-CD3 bi-specific antibodies) patent counsel until acquired for about 600 Mio USD by Cellgene;
  • WO2008118356 (antibody – alpha 4-integrin inhibitor) global patent prosecution on behalf of BIOGEN IDEC and UCB;
  • EP-B1 0 810 030 CLEMENS GmbH and PEQLAB GmbH ./. APPLERA patent infringement suit and opposition;

Exemplary Opposition proceedings before the EPO:

  • EP-B1 2 155 783 (AMGEN USA), CD3-epsilon binding domain, multiple opponents, Chugai, Roche, Pfizer, Affimed,
  • EngMAB, Janssen Biotech, Genmab;
  • EP-B1 0 639 228 (Baylor College), STR repeats in human identification, STRAWMAN;
  • EP-B1 0 960 207 (Promega Corp. USA), CODIS code in human identification, represented QIAGEN GmbH;
  • EP-B1 1 463 839 B1 (Norchip SA), HPv detection of 16, 18, 31, 33 and 45, represented QIAGEN GmbH;
  • EP-B1 1 913 157 (Hoffman La Roche), KRAS and EGFR for prediction of patient response to EGFR inhibitor, multiple opponents, Ely Lilly, Merck
  • USA, represented QIAGEN Manchester;
  • EP-B1 2 289 345 (Hofmeister KG), Cheese production, represented HOCHLAND SE
  • EP-B1 2 619 322 (Life Technologies), SE33 mutations impacting genotype concordance, represented QIAGEN GmbH
  • EP-B1 1 135 530 (Life Technologies), CODIS II, represented QIAGEN GmbH
  • EP-B1 2 394 617 (Paul Hartmann AG), Biomatrix with collagen, represented MEDSKIN Solutions Dr. Suwelack AG;
  • EP-B1 814 982 (Oncolytics), Improved viral Purification Methods, represented JANSSEN vaccines NL;
  • EP-B1 2 940 044 (ABBvIE), Anti TNF alpha AB/40 EOW for Rheum Arth. plus Methotrexate (HUMIRA), multiple opponents including HEXAL AG,
  • Biogen Inc., Mylan, AMGEN (USA), PAJARO, Pfizer and Samsung, acting as STRAWMAN;
  • EP-B1 2 325 304 (Epicentre), Polymerases in Next Generation Sequencing, STRAWMAN;
  • EP-B1 1 910 559 (Illumina, USA), Next Generation Sequencing, STRAWMAN;

Exemplary list of clients:
Max-Planck-Institutes (DE)
Fraunhofer Institutes (DE)
Johnson & Johnson (USA)
Genentech (USA)
Biogen Idec
ALvOTECH (Iceland)
Mylan (USA)
Schering AG (Berlin)
Hoffman la Roche (CH)
QIAGEN Manchester
Janssen vaccines (NL)
Takeda (Japan)
Charité (Berlin)
The Johns Hopkins University
Vanderbilt University
TEvA (Israel)
Celgene Corp. (USA)

Dr. Christian Kilger
t +49 30 886 20 07 – 0


  • Opposition and infringement proceedings
  • Biological as well as nucleic acid and protein based diagnostics
  • Food and beverages
  • Biomolecule based therapeutics
  • Due Diligence & Licensing/M&A